SciTech Development raised $5.5 million to advance ST-001 nanoFenretinide, a nanoparticle therapy for rare cancers including T-cell lymphoma. Its delivery platform improves drug effectiveness and safety, and the therapy has received FDA Orphan Drug Designation.
All entries for: SciTech Development
September 5, 2025
SciTech Development
Investment: Later Stage VC
SciTech Development raised $5.5 million to advance ST-001 nanoFenretinide, an FDA-designated orphan drug in clinical trials for the treatment of T-cell non-Hodgkin lymphoma, a rare and aggressive blood cancer.
Disease Area: Rare Diseases